Skip to content

Causes of Neutropenia: A Comprehensive Analysis with Focus on Hereditary Neutropenia

Overview

Neutropenia represents a critical hematologic disorder characterized by an Absolute Neutrophil Count (ANC) below 1500 cells/microL in adults. This condition significantly impacts the body's primary defense against bacterial and fungal infections, as neutrophils constitute the most abundant type of white blood cells and serve as the first line of innate immunity. The clinical significance of neutropenia extends beyond mere laboratory values, as it predisposes patients to life-threatening infections, with severity correlating directly with the degree of neutrophil depletion (Source: Chapter 64 - Harrison's Principles of Internal Medicine).

Pathophysiology

The development of neutropenia results from three fundamental mechanisms affecting neutrophil homeostasis:

  1. Decreased Production/Differentiation: Impairment in bone marrow production affects the myeloid lineage, leading to inadequate neutrophil generation. This mechanism underlies most congenital neutropenias and drug-induced cases.

  2. Peripheral Destruction: Enhanced destruction of circulating neutrophils through immune-mediated mechanisms, including antibody-mediated destruction and cytotoxic T-cell responses.

  3. Redistribution/Margination: Shift of neutrophils from the circulating pool to the marginated pool along vascular endothelium or sequestration in the spleen, effectively reducing the measurable ANC without true neutrophil depletion.

(Source: Approach to Neutropenia - UpToDate Clinical Guidelines)

Classification of Neutropenia Causes

Acquired Causes

Infectious Etiologies

Drug-Induced Neutropenia

Autoimmune and Inflammatory Disorders

Nutritional Deficiencies

(Source: Chapter 64 - Harrison's Internal Medicine, UpToDate Neutropenia Guidelines)

Constitutional Variants

The Duffy-null associated neutrophil count (DANC), formerly termed "benign ethnic neutropenia," represents a normal variant predominantly seen in individuals of African descent, affecting 4.5% of African Americans compared to 0.79% of White Americans. This condition results from homozygosity for the ACKR1 gene polymorphism and is not associated with increased infection risk despite ANC levels between 1000-1500 cells/microL (Source: Benign Ethnic Neutropenia - Blood Reviews).

Hereditary Neutropenia: Detailed Analysis

Severe Congenital Neutropenia (SCN)

Severe Congenital Neutropenia represents a heterogeneous group of inherited disorders characterized by:

Epidemiology

  • Incidence: 2-3 cases per million population
  • No sex predilection
  • Majority of patients are of European descent
  • Early onset, typically manifesting within the first months of life

Genetics and Molecular Pathogenesis

SCN demonstrates multiple inheritance patterns:

  1. Autosomal Dominant (60% of cases):
  2. ELANE mutations: Encoding neutrophil elastase, most common cause
  3. Mechanism: Misfolded protein triggers unfolded protein response and apoptosis

  4. Over 200 different mutations identified

  5. Autosomal Recessive:

  6. HAX1 mutations: Classic Kostmann syndrome
  7. G6PC3 mutations: Associated with cardiac and urogenital anomalies

  8. JAGN1 mutations: Causing aberrant myeloid homeostasis

  9. X-linked Recessive:

  10. WAS gene mutations: Wiskott-Aldrich syndrome variant
  11. TAZ mutations: Barth syndrome with cardiomyopathy

(Source: Congenital Neutropenia - Blood Journal, Severe Congenital Neutropenia Registry)

Clinical Presentation

Diagnostic Approach

  1. Laboratory Findings:
  2. ANC consistently <500 cells/microL, often <200 cells/microL
  3. Relative monocytosis and eosinophilia

  4. Normal hemoglobin and platelet counts initially

  5. Bone Marrow Examination:

  6. Maturation arrest at promyelocyte/myelocyte stage
  7. Reduced myeloid-to-erythroid ratio

  8. Absence of mature neutrophils

  9. Genetic Testing:

  10. Next-generation sequencing panels for neutropenia genes
  11. Family screening for identified mutations

Management

Prognosis and Complications

  • Myelodysplastic Syndrome/Acute Myeloid Leukemia Risk: 20% cumulative incidence by age 20
  • G-CSF Receptor Mutations: Associated with leukemic transformation
  • Quality of Life: Significantly improved with G-CSF therapy
  • Survival: >90% with appropriate treatment

Cyclic Neutropenia

Cyclic Neutropenia represents a rare autosomal dominant disorder characterized by regular oscillations in neutrophil counts:

Pathophysiology

  • ELANE Mutations: Similar to SCN but distinct mutation spectrum
  • Oscillating Hematopoiesis: 21-day cycles (range 14-35 days)
  • Accelerated Apoptosis: Of neutrophil precursors during nadir

Clinical Features

  • Periodic Symptoms: Fever, aphthous ulcers, lymphadenopathy
  • Timing: Symptoms coincide with neutrophil nadir
  • Well Periods: Complete resolution between cycles
  • Milder Course: Compared to SCN

Diagnosis

  • Serial CBC Monitoring: 2-3 times weekly for 6-8 weeks
  • Documentation: ANC <200 cells/microL during nadir
  • Genetic Testing: ELANE sequencing confirms diagnosis

Management

  • G-CSF Therapy: Lower doses than SCN (1-3 mcg/kg)
  • Prophylactic Antibiotics: During anticipated nadir periods
  • Prognosis: Excellent with minimal leukemia risk

Other Hereditary Neutropenia Syndromes

Shwachman-Diamond Syndrome

WHIM Syndrome

  • Acronym: Warts, Hypogammaglobulinemia, Infections, Myelokathexis
  • Gene: CXCR4 gain-of-function mutations
  • Pathology: Neutrophil retention in bone marrow
  • Treatment: G-CSF, IVIG, consideration of CXCR4 antagonists

Glycogen Storage Disease Type 1b

Diagnostic Algorithm for Hereditary Neutropenia

  1. Initial Assessment:
  2. Detailed family history including consanguinity
  3. Physical examination for dysmorphic features

  4. Serial CBCs to establish pattern

  5. Secondary Testing:

  6. Immunoglobulin levels
  7. Autoantibody screening

  8. Bone marrow aspiration and biopsy

  9. Genetic Evaluation:

  10. Targeted gene panels based on phenotype
  11. Whole exome sequencing for unclear cases

  12. Family member testing

  13. Functional Studies:

  14. Neutrophil function tests
  15. Flow cytometry for adhesion molecules
  16. Cytokine profiling

Management Principles

Infection Prevention

Growth Factor Therapy

Surveillance for Complications

Future Directions

Gene Therapy

Novel Therapeutics

Conclusion

Neutropenia represents a complex clinical entity with diverse etiologies ranging from benign ethnic variants to life-threatening congenital disorders. Hereditary neutropenias, while rare, provide crucial insights into neutrophil biology and hematopoiesis. The successful management of these conditions requires comprehensive diagnostic evaluation, including genetic testing, and long-term multidisciplinary care. The advent of G-CSF therapy has transformed outcomes, though challenges remain regarding leukemic transformation and quality of life. Ongoing research into gene therapy and targeted molecular approaches offers hope for curative treatments. Understanding these disorders is essential for clinicians, as early recognition and appropriate management can prevent life-threatening infections and optimize long-term outcomes.

References

(Sources: Chapter 64 - Harrison's Principles of Internal Medicine, Congenital Neutropenia Guidelines - Blood Journal, Severe Chronic Neutropenia International Registry, UpToDate - Approach to Neutropenia, Cyclic Neutropenia - NEJM, Hereditary Neutropenia Syndromes - Nature Reviews)